NCT04674423View on ClinicalTrials.gov

The Effectiveness and Safety of Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase and Significant Liver Injury.

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 14, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Hepatitis b
Interventions
DRUG

Tenofovir Alafenamide

Tenofovir Alafenamide treatment for 144 weeks

Trial Locations (1)

704

RECRUITING

National Cheng-Kung University Hospital, Tainan City

All Listed Sponsors
lead

National Cheng-Kung University Hospital

OTHER